Skip to main content

Immucell Value Stock - Dividend - Research Selection

Immucell

ISIN: US4525253062 , WKN: 885825

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ImmuCell Corporation, an animal health company, develops, acquires, manufactures, and sells products that enhance the health and productivity of dairy and beef cattle in the United States and internationally. The company primarily offers First Defense, an orally delivered scours preventive product for newborn calves. It also provides California Mastitis Test, which is used to detect somatic cell counts in milk, as well as to determine, which quarter of the udder is mastitic. In addition, the company is involved in developing purified Nisin treatment for subclinical mastitis in lactating dairy cows; and selling various product applications of its First Defense Technology, including a whey protein concentrate for the nutritional and feed supplement markets. ImmuCell Corporation sells its products to animal health distributors, fleet stores, and direct to farms. The company was founded in 1982 and is headquartered in Portland, Maine.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


ImmuCell Reports Y/Y Q1 Earnings Growth on Record Sales & Margin Gains

2025-05-19
ICCC posts record Q1 sales, returns to earnings and expands margins y/y as First Defense demand grows and production issues subside.

ImmuCell Corp (ICCC) Q1 2025 Earnings Call Highlights: Record Sales and Strategic Growth Amid ...

2025-05-16
ImmuCell Corp (ICCC) reports an 11% increase in product sales and improved gross margins, while addressing ongoing operational risks and strategic investments.

ImmuCell First Quarter 2025 Earnings: EPS: US$0.16 (vs US$0.056 loss in 1Q 2024)

2025-05-16
ImmuCell ( NASDAQ:ICCC ) First Quarter 2025 Results Key Financial Results Revenue: US$8.07m (up 11% from 1Q 2024). Net...

ImmuCell Corporation (ICCC) Q1 2025 Earnings Call Transcript

2025-05-15
ImmuCell Corporation (NASDAQ:ICCC) Q1 2025 Earnings Conference Call May 15, 2025 9:00 AM ETCompany ParticipantsJoe Diaz - Managing Partner, Lytham Partners,...

ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025

2025-05-14
PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 m

ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025

2025-05-12
Conference Call Scheduled for Thursday, May 15, 2025 at 9:00 AM ETPORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025

The Zacks Analyst Blog Netflix, SAP SE, Shell, Preformed Line Products and ImmuCell

2025-04-17
Netflix, SAP SE, Shell, Preformed Line Products and ImmuCell are included in this Analyst Blog.

ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025

2025-04-08
PORTLAND, Maine, April 08, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line resu

ImmuCell Hires Chief Financial Officer

2025-04-07
PORTLAND, Maine, April 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer. Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with I

ImmuCell Full Year 2024 Earnings: US$0.26 loss per share (vs US$0.74 loss in FY 2023)

2025-04-03
ImmuCell ( NASDAQ:ICCC ) Full Year 2024 Results Key Financial Results Revenue: US$26.5m (up 52% from FY 2023). Net...